Syros Pharmaceuticals Inc
NASDAQ:SYRS
Syros Pharmaceuticals Inc
Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 124 full-time employees. The company went IPO on 2016-06-30. The firm is focused on redefending the power of small molecules to control the expression of genes. The firm is engaged in developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases, and building a clinical-stage pipeline of gene control medicine. The firm's lead product candidates include Tamibarotene, SY-2101 and SY-5609. Its Tamibarotene, is a selective retinoic acid receptor alpha (RARα), agonist RARA-positive patients with higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML). Its SY-2101, is an oral form of arsenic trioxide (ATO) being developed for the treatment of acute promyelocytic leukemia (APL). Its SY-5609, is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) which is being development for patients with select solid tumors and blood cancers.
Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 124 full-time employees. The company went IPO on 2016-06-30. The firm is focused on redefending the power of small molecules to control the expression of genes. The firm is engaged in developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases, and building a clinical-stage pipeline of gene control medicine. The firm's lead product candidates include Tamibarotene, SY-2101 and SY-5609. Its Tamibarotene, is a selective retinoic acid receptor alpha (RARα), agonist RARA-positive patients with higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML). Its SY-2101, is an oral form of arsenic trioxide (ATO) being developed for the treatment of acute promyelocytic leukemia (APL). Its SY-5609, is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) which is being development for patients with select solid tumors and blood cancers.
No Q3 Revenue: Syros reported zero revenue for Q3 2024, down from $3.8 million last year due to the end of its Pfizer collaboration.
Major Data Milestone: The pivotal Phase III SELECT-MDS-1 trial data for tamibarotene in higher-risk MDS is expected in mid-November, viewed as a potentially transformative event for the company.
Significantly Lower Net Loss: Net loss dropped to $6.4 million ($0.16 per share) from $40.1 million ($1.43 per share) in Q3 2023, reflecting reduced R&D and G&A expenses.
Strong Cash Position: Syros ended Q3 with $58.3 million in cash, expected to fund operations into Q3 2025.
Focus on Tamibarotene: The company is preparing for an NDA filing and commercial launch, citing a US market opportunity over $800 million for tamibarotene in higher-risk MDS with RARA overexpression.
